Timber Pharmaceuticals (NYSE: TMBR) rose 23.97% to $1.5 in the after-market session. This stock has wildly shifted this year, with buyers keen to raise stock rates for simple business news or no news at all.
Nevertheless, on December 10, 2020, A biopharmaceutical corporation focusing on the production and commercialization of therapies for rare and orphan dermatological disorders revealed that it would host a corporate update conference call for analysts and shareholders.
Timber’s Chief Executive Officer, John Koconis, and Chief Financial Officer, Joe Lucchese, will host the call.
Conference Call Information
It will be held on Thursday, December 17th, at 11:00 am EST.
To join the call: Contact (877) 270-2148 and ask to be joined into the Timber Pharmaceuticals call.
There will also be a live webcast of the conference call, which can be accessed at:
https://services.choruscall.com/links/timberpharma201217.html For those unable to
participate in the live conference call; a replay will be archived and available on
Timber’s website under the Investor Relations tab at www.timberpharma.com.